Squarepoint’s Upstream Bio Inc UPB Stock Holding History

Squarepoint’s Portfolio UPB Stock Details UPB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Buy	290,904 +246,278	+552%	+$2.06M	﹤0.01%	2343
2026 Q1	$402K	Buy	+44,626	New	+$803K	﹤0.01%	3480

Other funds holding UPB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Squarepoint's UPB Position: Q2 2026 in Review

Squarepoint increased its Upstream Bio Inc (UPB) stake by 552% in Q2 2026, buying an estimated $2.06M and bringing the position to 290,904 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Squarepoint first reported a position in UPB in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold UPB as of Q2 2026.

Squarepoint held 290,904 shares of Upstream Bio Inc worth $2.01M as of Q2 2026.
Squarepoint bought 246,278 Upstream Bio Inc shares in Q2 2026, an estimated $2.06M.
Upstream Bio Inc made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2343 holding.
Squarepoint first reported a position in Upstream Bio Inc in Q1 2026 and has held it in 2 quarters since.
149 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.